Mylan N.V. (NASDAQ: MYL) is a large market cap stock with a market cap of 20529.35. It is in the Drugs – Generic industry and sector Healthcare, with a current P/E of 24.18, a forward P/E of 6.62 and EPS of 1.57. At a stock price of 38.03 (0.16%) it has a dividend yield of *TBA.
EPS growth for the last five years have been 20.20%, more recently this last year it has grown by -31.50%. The next year growth is going to be about 15.96% and more long-term 13.08% after five years. EPS growth quarter over quarter is 2.80%. Sales growth for the past five years have been 11.60% and sales growth quarter over quarter is 8.00%.
For performance, Mylan N.V. the past week has seen a gain of -5.45%. For the last month performance for Mylan N.V. is -5.87%. While the last quarter is -12.97% and half year, -20.89%. Finally for the year, performance is -11.25%.
The 52-week high for Mylan N.V., is at -31.49%, and for the 52-week low it comes to a value of 1.66%. The 20-day simple moving average is -13.54% and -17.20% for the 200-day simple moving average.
Volatility for the week is at 3.04%, and for the month it is 2.48%. Mylan N.V., has a target price of 56.
In terms of debt, long term debt/equity is 1.24, and for total debt/equity Mylan N.V. has 1.31. The gross margin is 45.30%, while operating margin is 15.70%, the profit margin is 8.10%. The current ratio is 3.2 and the quick ratio is 2.6.
Insider ownership is at 0.50%, with instituitional ownership at 64.50%. Mylan N.V. has a payout ratio of 0.00%. With the total shares outstanding coming to 539.82. The shares float is 438.9, with the float short at 5.77%, with short ratio coming to 4.21.
In terms of returns, the return on assets see Mylan N.V., get 3.40%, with its returns on investment at 8.20%. Return on equity is 8.00%. So will the investors see the target price of 56, reached soon?
Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.